ReliNethra® C is an autologous bio-engineered
composite conjunctival epithelial cell
graft comprising of conjunctival epithelial
stem cells cultured ex-vivo on an extracellular
carrier matrix for treating conjunctival
disorders.
It is prepared from the conjunctival biopsy
excised from the superior fornix preferably
of contralateral healthy eye of the patient.
It results in re-epithelialization of
the damaged or diseased conjunctival surface.
ReliNethra® C is composed of conjunctival
epithelial stem cells grown on denuded
human amniotic membrane with scattered
explants.
It is a 4 cm2 denuded human amniotic membrane
with autologous conjunctival epithelial
cells expanded from conjunctival explants.
ReliNethra® C transplant leads to
renewal of ocular surface epithelial cells
thereby replacing the damaged ocular surface
with smooth and healthy cells.
Conjunctival stem cell transplant results
in restoration of physiological and functional
conjunctival epithelium of the damaged
or diseased eye.
ReliNethra® C is indicated in patients
with damaged or diseased conjunctival
surface requiring surgical correction
of pterygium, symblepharon, chronic allergic
conjunctivitis, toxic epidermal necrolysis,
wide field excision of tumours, and/or
chemical injuries.
The protocol of the product includes Agreement
with the doctor, informed consent of the
patient, planning for conjunctival biopsy
of the same patient, processing into the
ReliNethra® C graft and planning the
transplantation in the affected eye.
